Parkinson’s disease: Cerevance outlines Phase II/III trial planned for Q1 2023
Cerevance CMO Jordan Dubow shares exclusive details on the first of two planned registrational trials in Parkinson’s disease.
By
William Newton
William Newton is a senior reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, rare diseases, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Latest articles
All Articles
Biogen caves in on Aduhelm: how Alzheimer’s disease biotechs can avoid similar mistakes
After Biogen all but waved the white flag on its once-promising Aduhelm, Clinical Trials Arena explores how Alzheimer’s disease…
By
Drug development for ultra-rare diseases: What happens when N=1?
Some ultra-rare diseases have fewer than 30 known patients globally. Is there an ethical and economical way to test…
By
ALS: Clene plans 300-patient Phase III trial of CNM-Au8
CNM-Au8 clinical advisor Matthew Kiernan previews Clene’s planned Phase III ALS trial design, including biomarkers and target population.
By
NeuroSense previews Phase IIb trial plans for oral ALS drug
NeuroSense CEO Alon Ben-Noon reveals the target patient population and outcome measures of a planned Phase IIb ALS trial…
By
Mapping Endpoints: Is the 6-minute walk test still the best Pompe disease clinical trial endpoint?
The 6-minute walk test has long been the consensus primary measure for Pompe disease drug studies, but some experts…
By
ALS clinical trials: How stem cells could fuel biomarker development
BrainStorm Cell Therapeutics is generating stem cells to test its ALS drug in a genetic subpopulation after missing the…
By
Rare Disease Day: Six clinical trial stories you need to read
We highlight our coverage on amyotrophic lateral sclerosis, Huntington’s disease, Rett syndrome, and achondroplasia for Rare Disease Day.
By
Pipeline Moves: Aslan’s shot at approval jumps in gastric cancer after Phase II/III completion
We also review Regenxbio in mucopolysaccharidosis type I and four Phase I trial updates.
By